Alto Neuroscience, Inc.

NYSE:ANRO

Biotechnology

Healthcare
$25.91 +1.84%

+$0.40 today

Market cap
$1.04B
Beta
1.25
P/E (TTM)
-9.8
EPS (TTM)
-$2.26
52W Low $2.15High $28.44

Volume 0.99M

Average 0.34M

ANRO Total Debt

Short-term and long-term borrowings combined.

Alto Neuroscience, Inc.NYSE: ANRO

Total Debt · Q1 FY2026 · quarter ended Mar 2026

Total debt falls 78.5% from a year ago

Total debt stood at $5.69M at the end of Q1 FY2026, down 78.5% from a year earlier and down 76.2% from the prior quarter. Over 3 fiscal years it compounded at -62.3% a year.

Context

  • Total debt amounted to 2.1% of total assets at the end of Q1 FY2026, down 13.3 pp from a year earlier.
  • Total debt increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total debt keeps falling in the next quarterly balance sheet after a -78.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.69M-76.2% QoQ
Last fiscal yearDec 2025
$4.41M-74.0% YoY
Year agoMar 2025
$26.44M-78.5% since
Total Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-78.5%——
1 year-74.0%——
3-year CAGR-62.3%——
5-year CAGR——
10-year CAGR——

Total Debt history

USD · from the balance sheet

Latest · FY2025
4.41M USD
Year-over-year change
-74.0%
4-year CAGR
-41.7%

Total Debt vs competitors

How ANRO compares with its peers on the latest reported figures

  • Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -78.5% is the lowest of 11, against a peer median of +7.8%.
  • Total debt amounts to 2.1% of total assets for ANRO, versus a peer median of 4.6%.
ANRO Competitors
Total Debt for ANRO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CLLSCellectis S.A.Mar 2026$108.6M USD+18.3%+16.5%37.6%
KRROKorro Bio, Inc.Mar 2026$42.89M USD-5.1%-36.1%23.4%
DBVTDBV Technologies S.A.Mar 2026$16.3M USD+32.0%+73.5%6.1%
ALDXAldeyra Therapeutics, Inc.Mar 2026$15.51M USD-0.3%-1.2%23.3%
DRTSAlpha Tau Medical Ltd.Mar 2026$14.34M USD+16.7%+38.3%13.2%
CTNMContineum Therapeutics, Inc. Class A Common StockMar 2026$6.95M USD+15.9%+12.1%2.7%
ANROAlto Neuroscience, Inc.Mar 2026$5.69M USD-78.5%-62.3%2.1%
AMRNAmarin Corporation plcMar 2026$5.59M USD-29.7%+6.7%0.9%
ACIUAC Immune S.A.Mar 2026CHF 4.3M CHF-16.8%+17.5%3.1%
LRMRLarimar Therapeutics, Inc.Mar 2026$3.78M USD-22.3%-9.1%1.8%
SLNSilence Therapeutics plcMar 2026$136K USD+126.7%-28.9%0.1%
Peer median (excluding ANRO) —+7.8%+9.4%4.6%

Competitors are the stored peer set for ANRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents25.71M48.34M82.55M168.23M176.48M
Short-term Investments00000
Net Receivables1.74M546K8K00
Inventory00000
Other Current Assets002.31M30K1.23M
Total Current Assets27.68M49.22M85.39M169.34M177.72M
Property, Plant & Equipment (Net)1.06M1.58M1.11M7.7M6.13M
Goodwill00000
Intangible Assets00000
Long-term Investments000500K500K
Tax Assets00000
Other Non-current Assets50K55K131K4K338K
Total Non-current Assets1.11M1.63M1.24M8.21M6.97M
Total Assets28.79M50.85M86.63M177.54M184.69M
Account Payables600K1.61M1.07M1.58M1.88M
Short-term Debt0283K00585K
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities1.19M3.54M008.86M
Total Current Liabilities1.81M5.56M5.61M10.01M11.33M
Long-term Debt38.16M81.7M9.86M11.56M3.82M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities1.3M1.88M142.83M018.4M
Total Non-current Liabilities39.46M83.7M152.69M16.07M22.22M
Total Liabilities41.27M89.26M158.3M26.08M33.55M
Common Stock1K1K03K3K
Retained Earnings(12.95M)(40.66M)(76.97M)(138.4M)(201.63M)
Accumulated OCI(22K)(46K)(79K)(101K)22K
Other Stockholders Equity00000
Minority Interest00000
Total Equity(12.48M)(38.41M)(71.67M)151.46M151.14M
Total Debt38.16M82.11M9.99M16.94M4.41M
Net Debt12.46M33.76M(72.56M)(151.29M)(172.08M)

Alto Neuroscience, Inc.

NYSE:ANRO

Intrinsic Alpha fair value

Locked

Current Price

$25.91

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.